A new observational analysis of industry press releases has found that resigning from a major drugmaker is strongly associated with accepting a higher-paying role at a rival biotech firm, though researchers emphasize these early findings are not definitive.
The data, derived from the latest STAT+ newsletter tracking corporate comings and goings, followed a cohort of 42 mid-to-senior level managers over a single fiscal quarter. While a study found a high correlation between executives cleaning out their desks at Merck and subsequently updating their LinkedIn profiles to reflect new C-suite titles at smaller startups, experts caution against drawing hasty conclusions from a purely observational design.
While we are seeing a statistically significant cluster of vice presidents moving up the ladder, we cannot definitively say that leaving one job causes a person to start another.
Dr. Thorne noted that because the employment updates are largely self-reported by the executives themselves, the findings carry a substantial risk of bias and differ significantly from a recent peer-reviewed JAMA paper on standard corporate attrition. Furthermore, the protocol used by industry publications to track these transfers often fails to control for confounding variables, such as lucrative severance packages or the sudden desire to spend more time with family, which the NIH recognizes as a known risk factor for abrupt career transitions.
At this time, the FDA has not updated the guidance on how to interact with the newly promoted executives. Until a randomized clinical trial can be conducted to verify these individuals are actually attending meetings at their new corporate headquarters, public health officials suggest the most prudent course of action is to withhold congratulatory messages, noting that, as always, more research is needed.